Abstracts tagged "interferon"

Abstract Number: 1949 • ACR Convergence 2020
CB2 Receptor Distribution and Effects of LenabasumTM in Dermatomyositis In Vitro
Spandana Maddukuri¹, Jay Patel², Christina Bax³, Maria Wysocka³ and Victoria Werth⁴, ¹University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Montville, NJ, ²University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, ³University of Pennsylvania, Department of Dermatology, Philadelphia, ⁴University of Pennsylvania and Corporal Michael J. Crescenz Veterans Administration Hospital, Philadelphia
Background/Purpose: Dermatomyositis (DM) patients report poor quality of life due to disease activity and persistent itch. Lenabasum is an oral non-immunosuppressive, non-psychoactive cannabinoid type 2…
Abstract Number: 0284 • ACR Convergence 2020
Oxidative DNA Damage Accelerates Skin Inflammation in Pristane-induced Lupus Model
Gantsetseg Tumurkhuu¹, Shuang Chen², Erica Montano¹, Malcolm Lane², Michifumi Yamashita², Janet Markman², Luz Blanco³, Mariana Kaplan⁴, Kenichi Shimada², Timothy Crother², Mariko Ishimori², Daniel J Wallace¹, Caroline Jefferies⁵ and Moshe Arditi², ¹Cedars-Sinai Medical Center, Los Angeles, ²Cedars-Sinai Medical Center, Los Angeles, CA, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, Centreville, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ⁵Cedars-Sinai Medical Center, West Hollywood, CA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic inflammatory autoimmune disease in which type I interferons (IFN) play a key role. The IFN response can…
Abstract Number: 1067 • ACR Convergence 2020
Anti-Viral Proinflammatory Phenotype in Circulating Monocytes from Patients with Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Associated Interstitial Lung Disease
Takahisa Gono¹, Yuka Okazaki¹ and Masataka Kuwana², ¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Tokyo, Japan
Background/Purpose: Anti-melanoma differentiation-associated gene 5 (MDA5) antibody is associated with interstitial lung disease (ILD), which often represents rapidly progressive course and fatal outcomes. Circulating levels…
Abstract Number: 009 • 2020 Pediatric Rheumatology Symposium
Emapalumab (Anti-Interferon-Gamma Monoclonal Antibody) in Patients with Macrophage Activation Syndrome (MAS) Complicating Systemic Juvenile Idiopathic Arthritis (sJIA)
Fabrizio De Benedetti¹, Paul Brogan ², Claudia Bracaglia ¹, Manuela Pardeo ¹, Giulia Marucci ¹, Emanuela Sacco ¹, Despina Eleftheriou ³, Charalampia Papadopoulou ³, Alexei Grom ⁴, Pierre Quartier ⁵, Rayfel Schneider ⁶, Philippe Jacqmin ⁷, Rikke Frederiksen ⁸, Maria Ballabio ⁹ and Cristina de Min ⁸, ¹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, ²UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ³UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, Section Head Infection, Immunology, and Rheumatology, London, United Kingdom, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, ⁵Paris-Descartes University, IMAGINE Institute, RAISE reference centre, Pediatric Immuno-Hematology and Rheumatology Unit, Necker hospital, Assistance Publique-Hôpitaux de Paris, Paris, France, ⁶The Hospital for Sick Children, Toronto, Canada, ⁷MnS Modelling and Simulation, Dinant, Belgium, ⁸Swedish Orphan Biovitrum AG (Sobi), Basel, Basel-Stadt, Switzerland, ⁹Swedish Orphan Biovitrum AG (Sobi), Basel, Switzerland
Background/Purpose: MAS is a severe complication of rheumatic diseases and occurs most frequently in patients with sJIA. Data from animal models and from observational studies…
Abstract Number: 5 • 2019 ACR/ARP Annual Meeting
Interferon Kappa Promotes the Development of Psoriasis
Mehrnaz Gharaee-Kermani¹, Shannon Estadt ¹, Sonya Wolf-Fortune ¹, Johann Gudjonsson ¹ and J. Michelle Kahlenberg ¹, ¹University of Michigan, Ann Arbor, MI
Background/Purpose: Psoriasis is a one of the most common chronic inflammatory autoimmune skin diseases characterized by hyperproliferation and abnormal differentiation of keratinocytes and infiltration of…
Abstract Number: 1021 • 2019 ACR/ARP Annual Meeting
Anti-IFNAR Treatment Does Not Reverse Neuropsychiatric Disease in MRL/lpr Lupus Mice
Michelle Huang¹, Ariel Stock ², Elise Mike ², Roland Kolbeck ³ and Chaim Putterman ⁴, ¹Albert Einstein College of Medicine, Bronx, ²Albert Einstein College of Medicine, Bronx, NY, ³MedImmune, Gaithersburg, MD, ⁴Albert Einstein College of Medicine, New York, NY
Background/Purpose: Many systemic lupus erythematosus patients display a type I interferon (IFN) signature, and IFNα levels and gene signatures have been positively correlated with disease…
Abstract Number: 1059 • 2019 ACR/ARP Annual Meeting
BDCA2 Targeting of Human Plasmacytoid Dendritic Cells via CBS004 Reverts Dependent IFN Activation and Tissue Fibrosis in vitro and in vivo
Rebecca Ross¹, Clarissa Corinaldesi ², Gemma Migneco ³, Yasser El-Sherbiny ⁴, Steve Holmes ⁵, Jörg Distler ⁶, Clive McKimmie ⁷ and Francesco Del Galdo ⁸, ¹Univesristy of Leeds, Leeds, England, United Kingdom, ²University of Leeds, Leeds, England, United Kingdom, ³University of Leeds, Leeds, United Arab Emirates, ⁴University of Nottingham, Nottingham, United Kingdom, ⁵Capella Bioscience, london, United Kingdom, ⁶Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ⁷University of Leeds, Leeds, United Kingdom, ⁸University of Leeds and LTHT NIHR Biomedical Research Centre, Leeds, United Kingdom
Background/Purpose: Human plasmacytoid dendritic cells (pDCs) have been implicated in the pathogenesis of Systemic Sclerosis (SSc) through their ability to infiltrate the skin and secrete…
Abstract Number: 1765 • 2019 ACR/ARP Annual Meeting
Interferon-gamma Supports Transcriptional Activity of BIRC5 in CD4+ T Cells in Established Rheumatoid Arthritis
Malin Erlandsson ¹, Karin Andersson ¹, Nisha Nair ², Anastasius Damdimopoulos ³, Sofia Silfverswärd ¹, Rille Pullerits ¹, Anne Barton ² and Maria Bokarewa¹, ¹Department of Rheumatology and Inflammation Research, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, Gothenburg, Sweden, ²Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK, Manchester, United Kingdom, ³Department of Biosciences and Nutrition, Karolinska Institute, Solna, Sweden, Stockholm, Sweden
Background/Purpose: It is known that rheumatoid arthritis (RA) should be treated early and a delay in treatment increases the rate of treatment non-response, joint damage,…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].